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Abstract
Hepatocellular carcinoma (HCC) is one of the major malignancies worldwide and is associated with poor prognosis due to
the high incidences of metastasis and tumor recurrence. Our previous study showed that overexpression of p21-activated
protein kinase 1 (PAK1) is frequently observed in HCC and is associated with a more aggressive tumor behavior, suggesting
that PAK1 is a potential therapeutic target in HCC. In the current study, an allosteric small molecule PAK1 inhibitor, IPA-3,
was evaluated for the potential in suppressing hepatocarcinogenesis. Consistent with other reports, inhibition of PAK1
activity was observed in several human HCC cell lines treated with various dosages of IPA-3. Using cell proliferation, colony
formation and BrdU incorporation assays, we demonstrated that IPA-3 treatment significantly inhibited the growth of HCC
cells. The mechanisms through which IPA-3 treatment suppresses HCC cell growth are enhancement of apoptosis and
blockage of activation of NF-kB. Furthermore, our data suggested that IPA-3 not only inhibits the HCC cell growth, but also
suppresses the metastatic potential of HCC cells. Nude mouse xenograft assay demonstrated that IPA-3 treatment
significantly reduced the tumor growth rate and decreased tumor volume, indicating that IPA-3 can suppress the in vivo
tumor growth of HCC cells. Taken together, our demonstration of the potential preclinical efficacy of IPA-3 in HCC provides
the rationale for cancer therapy.
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Introduction
As the sixth most common malignant tumor and the third
leading cause of cancer mortality worldwide, hepatocellular
carcinoma (HCC) is responsible for more than a million deaths
annually [1]. HCC is associated with poor prognosis due to high
incidences of tumor recurrence and metastasis [2]. Liver resection
is one of the major therapies at present but remains unsatisfactory
because of the high recurrence rates [3]. Therefore, the
development of novel treatment regimens for HCC is required.
Overexpression of p21-activated kinase 1 (PAK1) is frequent
in HCC [4]. It is a downstream effector of the small Rho
GTPase, including Rac1 and Cdc42, which regulates diverse
cellular processes, including cell cycle progression, cell motility,
cell polarity and apoptosis [5]. Activated Rho GTPase binds to
PAKs on the Cdc42/Rac interactive binding (CRIB) domain,
causing the relief of autoinhibitory domain (AID), subsequent
autophosphorylation of the catalytic domain and kinase
activation [6]. Among the multiple autophosphorylation sites,
threonine-423 (T423) is particularly important for counteracting
autoinhibition and maintaining the complete activated state [7].
IPA-3 (2,29- dihydroxy-1,19-dinaphthyldisuifide) is a highly
selective, non-ATP-competitive allosteric inhibitor of PAK1 whose
hyperactivity has been shown to be closely related with tumori-
genesis [8]. Previous studies demonstrated that IPA-3 prevented
Cdc42-induced PAK1 autophosphorylation on T423 and signif-
icantly inhibited PAK1 catalytic activity [8,9]. The inhibitory
action of IPA-3 is achieved in part by binding covalently to the
regulatory domain of PAK1 which in turn prevented the physical
interaction with Cdc42 or other GTPase activators [9]. IPA-3-
targeting regulatory domain is less conserved within kinases, thus
confers a remarkably high selectivity to this inhibitor [8]. In vitro
studies showed that IPA-3 treatment led to similar results as
siRNA silencing of PAK1, in which IPA-3 specifically blocked the
membrane transport of WAVE2 and lamellipodia formation in
human breast cancer cells [10], and inhibited the endocytic uptake
of human adenovirus serotype 35 in various cell lines [11].
However, the effect of IPA-3 in the therapeutic treatment of
human HCC is still poorly understood. In this study, we aimed to
investigate the potential of IPA-3 in suppressing the proliferation
and metastasis of human HCC cells through a series of in vitro and
in vivo experiments. We showed that treatment of IPA-3 had a
significant impact on the apoptosis, proliferation and motility of
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Figure 1. Inhibitory effect of IPA-3 on PAK1. (A) Relative protein levels of PAK1 in various cell lines. The signal intensities of the bands were
quantified and normalized by taking that level of MIHA as 1. (B) MTT assay on Day 1 and 2. H2M cells (46103) were seeded onto 96-well plates and
treated with different dosages of IPA-3. The cells were harvested after incubation and the MTT assay was performed as mentioned in Material and
Method. The graph showed the percentage of viable cells plotted against the dosage of IPA-3 (C) Western blotting analysis of the P-PAK1, total PAK1,
P-JNK and total JNK. Serum-starved H2M cells were treated with either DMSO or IPA-3 at the indicated concentration for 15 minutes and followed by
FBS replenishment and overnight culture. (D) H2M cells were serum-starved and treated with IPA-3 (10, 20 or 40 mM) in complete medium and
allowed to grow overnight. The cell morphology images were captured at a magnification of 40X. Scale bar, 0.4 mm.
doi:10.1371/journal.pone.0068843.g001
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HCC cells. Furthermore, IPA-3 was able to suppress the in vivo
tumor growth in nude mouse xenografts. Therefore, our data
provides supportive evidences for the potential application of IPA-
3 in managing tumorigenesis and metastasis of HCC.
Materials and Methods
Chemicals
2,29-dihydroxy-1,19-dinaphthyldisuifide (IPA-3) was synthesized
and provided by Dr. L.L. Yeung in Hong Kong University of
Science and Technology. The structure of IPA-3 was confirmed
by mass spectrometry analysis. A stock solution of IPA-3 (100 mM)
was freshly prepared in DMSO. Other chemicals unless specifi-
cally stated were from Sigma-Aldrich at the highest quality.
Cell Culture
Human HCC cells H2M, H2P and the human non-tumor-
igenic, immortalized liver line MIHA were from Dr. X.Y. Guan,
Department of Clinical Oncology, University of Hong Kong,
Pokfulam, Hong Kong [12]. MHCC97L and MHCC97H cells
were from Liver Cancer Institute, Fudan University, Shanghai,
China [13]. HepG2 and Hep3B cells were purchased from
American Type Culture Collection (ATCC). SMMC-7721 and
Bel-7402 were gifts from Shanghai Institute of Biochemistry and
Cell Biology, Chinese Academy of Sciences. All cells were grown
in Dulbecco’s modified Eagle minimal essential medium (DMEM)
with high glucose supplemented with 10% heat-inactivated fetal
bovine serum (FBS), 1 mM sodium pyruvate and 100 U penicil-
lin/streptomycin, at 37uC in humidified 5% CO2 incubator.
MTT Assay
Four thousand H2M cells per well were seeded in 96-well plates
and incubated in normal condition for 24 hours. Cells were treated
with different concentrations of IPA-3 for 1, and 2 days. Cells were
treated with 100 ml of 5 mg/ml of (3-(4,5-Dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) (Invitrogen) solution for
4 hours at 37uC until crystals were formed. MTT solution was
removed from each well and 100 ml of DMSO was added to each
well to dissolve the crystals. Color intensity was measured by
Microplate Reader (Bio-Rad) at 570 nm. Each experiment
consisted of four replications and at least three independent
experiments were carried out.
Cell Proliferation Assay
The method for proliferation assay was described previously [4].
The best fit growth curve and doubling time were calculated using
GraphPad Prism 5 (GraphPad Software, Inc., San Diego, CA).
Briefly, H2M (16104), H2P (16104), HepG2 (26104), MHCC97L
(16104) or MIHA (26104) cells were plated onto 6-well plates
containing complete medium on Day 0. Either vehicle control
(DMSO) or IPA-3 (5 or 10 mM) was added into the medium on
Day 1. Media with or without IPA-3 were refreshed on Day 3 and
5. In triplicates, cells were trypsinzed and counted using cell
counter on Day 3, 4, 6 and 7 for the construction of growth curve.
Colony Formation Assay
The assay was performed as described previously [14]. Briefly,
cells were seeded at 200 cells per well in 6-well plates containing
complete DMEM on Day 0. DMSO or IPA-3 (5 or 10 mM) was
administrated to the media, which were refreshed two times a
week. On Day 14, colonies were fixed with 3.7% formaldehyde for
15 minutes and stained with 1% crystal violet before quantifica-
tion.
BrdU Incorporation Assay
The assay was performed as described previously [15]. Cell
proliferation was quantified by the measuring the BrdU incorpo-
ration during DNA synthesis with the Cell Proliferation ELISA,
BrdU Colorimetric kit (Roche Diagnostics). The assay was
performed according to the manufacturer’s manual. In brief,
equal number of H2M, H2P, MIHA, HepG2 or MHCC97L cells
was plated in 96-well plates and serum-starved overnight. Serum
starvation induced cell-cycle synchronization so that most of the
cells stay in the G1/S transition just before the S phase entry. Cells
were then treated with either DMSO or various concentration of
IPA-3 (10 and 20 mM) for 15 minutes, followed by FBS
replenishment and BrdU labeling for 2, 4 or 8 hours. The BrdU
labeling signal was quantified by measuring the relative absor-
bance (Abs370 nm-Abs492 nm). Each assay was done in triplicate.
The experiments were performed at least three times indepen-
dently.
Annexin V-7ADD Staining Assay
Detection of apoptotic cell death was performed using the PE
Annexin V Apoptosis Detection Kit I (BD Pharmingen). In
triplicate, H2M cells were plated in 60 mm dish, serum-starved
overnight and then treated with DMSO or IPA-3 (10 or 20 mM) in
medium containing serum for 24 hours. Floating cells were washed
away, while the attached cells were trypsinized, rinsed and
resuspended in binding buffer. After staining with annexin V-PE
and 7-AAD, samples were immediately analyzed by flow
cytometry. Excitation: 488 nm (annexin V-PE and 7-AAD).
Emission: 578 nm (annexin V-PE), 675 nm (7-AAD). Cells were
counted per sample and the data were analyzed with WinMDI
(Version 2.8, Joe Trotter).
Confocal Microscopy
After drug treatment, H2M or H2P cells were fixed in 4%
paraformaldehyde for 15 minutes, washed, and permeabilized
with 0.2% Triton X-100 in PBS for 15 minutes [4,15]. Slides were
stained with TRITC-phalloidin (Invitrogen) for 10 minutes and
immunofluorescence imaging was captured in a Carl Zeiss
LSM700 laser confocal scanning microscope.
Transwell Migration Assay
Transwell migration assay was performed as described previ-
ously [4]. Briefly, H2M (16105) cells were plated in serum-free
DMEM at the upper compartment and serum-complemented
medium was added to the lower compartment of the Transwell
chamber (Corning). In the presence or absence of IPA-3 (10 mM),
the serum-starved cells were allowed to migrate for 24 hours. Cells
were then fixed with 3.7% formaldehyde, stained with 1% crystal
violet and counted under a microscopic field at the magnification
of 40X. Three different fields were randomly chosen for each
insert.
Quantitative Reverse Transcription-PCR (qRT-PCR)
Serum-starved H2M cells were treated with or without IPA-3
pretreatment (10 or 20 mM, 15 minutes) followed by TNF-a (10 or
20 ng/ml, 24 hours), FBS replenishment and overnight culture.
qRT-PCR was performed as described previously [4]. Briefly, total
RNA was extracted using Trizol (Invitrogen) according to the
manufacturer’s protocol. Total RNA was reverse transcribed into
first-strand cDNA using PrimeScript RT reagent Kit (Takara,
Japan). Real-time qPCR was performed using SYBRH Green Real
Time system (Takara, Japan) in a My IQTM2 Real-Time PCR
Detection System (Bio-Rad). b-actin was used as an internal
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Figure 2. IPA-3 suppressed cell proliferation. (A) The effect of IPA-3 on the cell proliferation rates of MIHA (upper, left panel), HepG2 (upper,
middle panel) H2P (upper, right panel), H2M (lower, left panel) and MHCC97L (lower, right panel) cells. Statistical analysis was performed by
comparing with the value of DMSO control. *P,0.05, **P,0.01 (ANOVA). (B) BrdU labeling assays of MIHA (upper, left panel), HepG2 (upper, middle
panel), H2P (upper, right panel), H2M (lower, left panel) and MHCC97L (lower, right panel) cells. *P,0.05 (ANOVA) compared with the DMSO control.
Error bars, mean 6 SD of triplicate samples. (C) Representative plates of colony formation assay of MIHA (left panel), HepG2 (middle panel) and H2M
cells (right panel). Bar chart of colony formation assay (lower panel). *P,0.001, **P,0.01 (ANOVA) compared with the DMSO control. Error bars, mean
6 SD of triplicate samples.
doi:10.1371/journal.pone.0068843.g002
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Figure 3. The induction of apoptosis by IPA-3. (A) Annexin V-7ADD staining assay. The fluorescence signals of annexin V-PE and 7-AAD were
detected with PE-A and Per-Cy5-5-A channels, respectively (upper panel). The percentage of H2M cells stained with annexin V-PE only under different
treatments was shown in a bar chart (lower panel). *P,0.001 (ANOVA) compared with the DMSO control. (B) Serum-starved H2M cells were treated
with increasing dosages of IPA-3 together with serum replenishment for 24 hours. Western blotting analysis of PARP1, P-PAK1 (T423), total PAK1 and
cleaved caspase 3 was performed.
doi:10.1371/journal.pone.0068843.g003
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control and allowed normalization of the samples. DNA sequences
of the PCR primers are listed in Table S1. qRT-PCR was
performed in triplicates and repeated three times.
Western Blotting Analysis
Protein extraction and Western blotting were conducted as
described previously [4,15]. Immunoblotting was done for PAK1,
P-PAK1 (T423), PARP1, Paxillin, P-Paxillin (S178), SAPK/JNK,
P-SAPK/JNK (T183/Y185), cleaved caspase 3 (Cell Signaling
Technology), NF-kB (Santa Cruz Biotechnology) and b-actin
(Sigma-Aldrich) followed by corresponding horseradish-peroxidase
(HRP) conjugated secondary antibodies (GE Healthcare). Signals
of targeted proteins were detected by Enhanced Chemiluminsence
(GE Healthcare). Intensities of protein bands were analyzed using
Adobe Photoshop CS4.
Nude Mouse Xenograft
MHCC97L cells (16106) were injected subcutaneously into the
right flank of 4-week-old male nude mouse. Tumor size was
calculated as described previously [4]. Mice with tumors of a mean
size of 100 mm3 were grouped into treatment cohorts. A total of
15 mice were used and divided into three groups (5 mice per
group): Control (DMSO), IPA-3 (2 mg/kg) and IPA-3 (4 mg/kg).
IPA-3 was formulated in DMSO and administrated three times
weekly (TIW) (2 mg/kg or 4 mg/kg) by intraperitoneal injection
(i.p.) during the study and the tumor size was recorded twice a
week. Animal studies had been specifically approved by Animal
(Control of Experiments) Ordinance Chapter 340, the Depart-
ment of Health, Hong Kong Special Administrative Region (Ref.:
(11–786) in DH/HA&P/8/2/3 Pt. 33).
Statistical Analysis
Experiments were done in triplicates and data were presented as
mean 6 SD. Student’s t-test was used for statistical analysis, and
data from more than two groups were analyzed by one-way
analysis of variance (ANOVA) in GraphPad Prism 6 followed by
Dunnett’s test. Results were considered significant when P,0.05.
Results
IPA-3 Inhibits the Activity of PAK1
HCC cells have been shown to have a high endogenous
PAK1 level, particularly in the highly metastatic HCC cell lines
[4], such as H2M, but not in the non-tumorigenic, immortal-
ized liver cells, MIHA (Fig. 1A). To investigate the effect of
IPA-3 on the growth of H2M cells, MTT assay was performed.
MTT assay demonstrated that IPA-3 suppressed the prolifera-
tion of H2M cells in time- and dose-dependent manners
(Fig. 1B). The half maximal inhibitory concentration (IC50) of
IPA-3 in H2M cells was about 28 mM and 21 mM on day 1
and 2, respectively. To confirm the inhibitory effect of IPA-3 on
PAK1 activity, H2M cells were serum-starved and then treated
with IPA-3 in complete medium overnight. The Western
blotting analysis showed that IPA-3 dose-dependently reduced
the phosphorylation level of PAK1 (Fig. 1C). Consistently, the
results showed IPA-3 causes a decrease in PAK1 phosphoryla-
tion in association with a decrease in H2M cell viability. In
addition, phosphorylation of the downstream substrate of PAK1,
c-Jun N-terminal kinase (JNK), was also reduced, further
supporting the reduction of PAK1 kinase activity by IPA-3
(Fig. 1C). Light microscopic examination of the IPA-3-treated
cells revealed pronounced morphologic changes. Fig. 1D
showed the morphologic changes in H2M cells after being
treated with IPA-3. In high dosages of IPA-3(20 and 40 mM), a
significant population of H2M cells became round-up and
detached from the dish.
IPA-3 Suppresses Proliferation of HCC Cells
To further evaluate the effect of IPA-3 on HCC cell
proliferation, two primary HCC cell lines, HepG2 and H2P,
two metastasis HCC cell lines,. H2M and MHCC97L, and the
non-tumorigenic, immortalized liver cell line, MIHA, were
separately treated with different dosages of IPA-3. In the cell
proliferation assay, treatment of IPA-3 significantly reduced the
number of metastatic HCC cells (H2M and MHCC97L) and a
lesser extent for the primary HCC cells (HepG2 and H2P),
scored in a dose-dependent manner (Fig. 2A). In contrast,
MIHA had the highest chemoresistance to IPA-3, suggesting
that IPA-3 could inhibit hepatoma cell proliferation with a little
effect on normal hepatocytes. To confirm the effect of IPA-3,
total cell lysates of H2M cells were collected on Day 7 and
tested for PAK1 inhibition by Western blotting analysis. The
result showed that IPA-3 treatment markedly inhibited the
activating phosphorylation of PAK1, suggesting that IPA-3
inhibits cell proliferation by reducing the PAK1 activity
(Supplementary Fig. S1). Consistently, concomitant reduction
of the phosphorylation of JNK, the downstream targets of
PAK1, was also observed (Fig. S1). To elucidate whether the
anti-proliferative mechanism of IPA-3 on HepG2, H2P, H2M
and MHCC97L cells was due to a decrease in cell cycle entry,
BrdU labeling assay was performed. In order to achieve a
prominent effect of IPA-3, 10 mM and a higher dosage (20 mM)
were used for the investigation. Our data showed that IPA-3
treatment on the synchronized H2M and MHCC97L cells
resulted in a significant reduction in the rate of BrdU
incorporation, as compared with the DMSO control in time-
and dose-dependent manners (Fig. 2B). However, IPA-3 only
had a marginal effect on the BrdU incorporation rate of H2P
and HepG2 cells, implicating that IPA-3 is highly specific for
the metastatic HCC cell lines. To further confirm the effect of
IPA-3 on the suppression of HCC cell growth, colony formation
assay was performed using non-tumorigenic (MIHA), primary
(HepG2) and metastatic (H2M) HCC cells. The result showed
that IPA-3 significantly inhibited the growth of HepG2 and
H2M cells, but merely had a very marginal effect on MIHA
cells (Fig. 2C). Noteworthy, MIHA cells, which have a very low
Figure 4. The suppressive effect of IPA-3 on migration of H2M cells. (A) Paxillin protein expression was detected by immunofluorescence
analysis under IPA-3 treatment. H2M and H2P (upper panel) cells were serum-starved overnight and treated with either DMSO control or IPA-3
(20 mM) for 15 minutes, followed by FBS replenishment for 10 minutes. Immunofluoresence signals of phalloidin (Red), paxillin (Green) and DAPI
(Blue) represent stress fiber, focal adhesion and nucleus, respectively (magnification 40X). The number of focal adhesion (paxillin) were counted in
H2M (lower, left panel) and H2P (lower, right panel), and represented in the bar chart. Error bars, mean 6 SD of triplicate samples. *P,0.01 (t-test)
compared with DMSO control. (B) Western blotting analysis on the phosphorylation levels of PAK1 and paxillin. Serum-starved cells were treated with
various concentrations of IPA-3 as indicated for 15 minutes, followed by FBS replenishment for 10 minutes. (C) Representative images of Transwell
migration assay of H2M cells. Cells were treated with either DMSO or 10 mM IPA-3, and were allowed to migrate for 24 hours. Images show the cells
having migrated to the lower chamber (upper panel). The number of migrated cells were counted and represented in the bar chart (lower panel).
Error bars, mean 6 SD of triplicate samples. *P,0.01 (t-test) compared with DMSO control.
doi:10.1371/journal.pone.0068843.g004
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endogenous level of PAK1, showed no difference in cell
proliferation upon IPA-3 treatment. Taken together, these
results indicated that IPA-3 treatment suppressed HCC cell
proliferation in a descending order of preference, metastatic
Figure 5. The inhibitory effect of IPA-3 on NF-kB nuclear translocation. (A) Effect of IPA-3 on subcellular localization of NF-kB was evaluated
by immunofluorescence staining. After overnight serum starvation, H2M (left panel) and MIHA (right panel) cells were treated with either DMSO or
IPA-3 (20 mM, 15 minutes) followed by an addition of TNF-a (20 ng/ml, 15 minutes). NF-kB was detected with a specific antibody (Green) and nucleus
was stained with DAPI (Blue). (B) Western blotting analysis of P-PAK1 (T423) and total PAK1 were detected in the H2M cells stimulated by TNF-a
(20 ng/ml) with or without IPA-3 pretreatment (20 mM, 15 minutes). TNF-a was included in the culture medium for 0, 0.5, 1, 2 or 4 hours. (C)
Expression of quantitative real-time PCR was performed to analyze the mRNA level of MMP-9 (left panel) and COX-2 (right panel). Serum-starved H2M
cells were treated with or without IPA-3 pretreatment (10 or 20 mM, 15 minutes) followed by TNF-a (10 or 20 ng/ml, 24 hours). Quantitative results of
MMP-9 and COX-2 mRNA levels were normalized to b-actin. The values represented the mean 6 SD of three independent experiments. *P,0.001
(ANOVA), ***P,0.05 (ANOVA) compared with the TNF-a control.
doi:10.1371/journal.pone.0068843.g005
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Figure 6. The suppressive effect of IPA-3 in nude mouse xenograft model. (A) MHCC97L cells were used for the xenograft model. Mice were
treated three times weekly either with DMSO or IPA-3 (2 mg/kg or 4 mg/kg, i.p.). *P,0.001 (ANOVA) compared with the DMSO control group. (B)
Tumor weights were measured at the end of study. *P,0.001, **P,0.01, (ANOVA) compared with the DMSO control group. (C) Representative results
of Western blotting analysis. P-PAK1 (T423), total PAK1, P-JNK and total JNK were detected. ***P,0.05 (ANOVA) compared with the DMSO control.
Error bars, mean 6 SD of 5 animals per group.
doi:10.1371/journal.pone.0068843.g006
IPA-3 Inhibits the Growth of Liver Cancer Cells
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HCC .primary HCC.non-transformed hepatocytes, and in a
PAK1-dependent manner.
IPA-3 Induces Apoptosis of HCC Cells
To investigate whether IPA-3 affects apoptosis in HCC cells, an
annexin V-7ADD staining assay was performed. Since 10 mM
IPA-3 inhibits proliferation rate and a higher concentration i.e.
20 mM causes a significant result in the BrdU incorporation assay
in H2M cells, 10 mM and 20 mM were used to investigate the
prominent effect of IPA-3. The result showed that incubation of
H2M cells with 20 mM IPA-3 led to a higher percentage of cells
displaying a positive signal of annexin V staining, as compared
with the DMSO control, suggesting that cells underwent apoptosis
under the treatment with IPA-3 (Fig. 3A). In addition, the
potential pro-apoptotic activity of IPA-3 was further examined by
the cleavage of PARP1 and caspase 3. Treatment of IPA-3 in
H2M cells resulted in an attenuated level of PARP at 20 mM and
the cleavage form of PARP1 could be detected at 40 mM (Fig. 3B).
This was accompanied with a dose-dependent reduction of PAK1
phosphorylation levels of PAK1 (Fig. 3B). In addition, the level of
cleaved caspase 3 increased in a dose-dependent manner. Taken
together, these results suggested that IPA-3 induces apoptosis
through PAK1 inhibition at a high concentration.
IPA-3 Suppresses HCC Cell Migration
PAK1 has a prominent role in cell migration, particularly in the
regulation of stress fibers formation and focal adhesions turnover.
Thus, immunofluorescence staining was performed to investigate
whether IPA-3 can influence these processes. IPA-3 was found to
enhance the formation of stress fibers and focal adhesions in both
H2M and H2P cells, which were visualized by the phalloidin and
paxillin immuno-positive signals of stress fibers and focal
adhesions, whereas the DMSO control showed a weak and
scattered staining. In addition, the results showed that treatment of
IPA-3 significantly enhanced the number of focal adhesion
complexes in H2M and H2P cells as revealed by paxillin staining
(Fig. 4A). Phosphorylation of paxillin at serine-178 (S178) is
important for PAK1-mediated cell migration, which has been
showed to be phosphorylated by JNK [4,16]. In H2M cells,
phosphorylation of paxillin at S178 was significantly reduced along
with an overnight treatment of IPA-3 (Fig. 4B). Thus, IPA-3
inhibits the signaling of the PAK1/JNK/paxillin pathway.
Moreover, a Transwell migration assay was performed to study
the effect of IPA-3 on the in vitro migration ability of H2M cells.
We found that IPA-3 significantly suppressed the migration of
H2M cells as the number of migrated cells was remarkably
reduced by 79%, as compared with the DMSO control (Fig. 4C).
Taken together, these data illustrated that IPA-3 significantly
reduces the PAK1-dependent cell mobility of HCC cells.
IPA-3 Suppresses NF-kB Nuclear Translocation
Previous reports demonstrated that PAK1 stimulates the activity
and subcellular translocation of nuclear factor light-chain
enhancer of activated B cells (NF-kB), and promotes cell survival
[17,18]. Thus, we examined whether IPA-3 is able to inhibit the
activity of NF-kB. H2M with a high endogenous expression level
of PAK1 and immortalized hepatocytes, MIHA cells were serum-
starved and then separately treated with IPA-3 followed by tumor
necrosis factor-alpha (TNF-a). As showed in Fig. 5A, NF-kB
positive staining was predominantly detected in the cytoplasm of
the DMSO control, whereas NF-kB staining was accumulated in
the nucleus after TNF-a induction. Interestingly, H2M cells
pretreated with IPA-3 resulted in a cytoplasmic staining of NF-kB,
indicating that IPA-3 suppressed the TNF-a-induced nuclear
targeting of NF-kB. Unlike H2M cells, IPA-3 did not suppress
TNF-a-induced NF-kB activation in MIHA cells, which lack the
endogenous PAK1. This result suggested that the inhibition of NF-
kB activation by IPA-3 is PAK1-dependent. To further investigate
whether PAK1 inactivation is involved in the IPA-3-induced
suppression of NF-kB translocation, phosphorylation of PAK1 was
determined (Fig. 5B). Consistent with an earlier study which
demonstrated that PAK1 was promptly activated by TNF-a in
various cell lines [19], the phospho-PAK1 level was elevated in
cells stimulated with TNF-a (20 ng/ml). The phosphorylation
level was highest at 0.5-hour and then gradually reduced
afterwards. On the other hand, the phosphorylation of PAK1
was completely suppressed in IPA-3 pretreated cells. This result
suggested that IPA-3 is able to abolish the PAK1 activation
induced by TNF-a, which correlated well with the IPA-3
inhibition on TNF-a-induced NF-kB translocation. The induction
of metalloproteinase (MMP)-9 by TNF-a was shown to be
mediated by PAK1 [19]. To elucidate the effect of IPA-3 on the
TNF-a-induced activity of MMP-9 and COX-2, which are
downstream targets of NF-kB [20,21], we performed qRT-PCR
to quantify the mRNA production of MMP-9 and COX-2. After
normalization with b-actin, H2M cells responded to TNF-a with
an increasing mRNA production of MMP-9 and COX-2 (Fig. 5C).
However, the results showed that treatment of IPA-3 significantly
suppressed the expression of MMP-9 and COX-2 transcripts in a
dose dependent manner.
IPA-3 Suppresses Tumorigenesis in Nude Mouse
Xenograft Model
The breadth of IPA-3 antitumor activity in vivo was evaluated
using a nude mouse xenograft model. Since the H2M cell line was
unable to develop solid tumors in nude mice, another human
HCC line MHCC97L with similar PAK1 level was used (Fig. 1A).
Following tumor establishment (100 mm3), five mice per groups
were treated with either DMSO or various doses of IPA-3 (2 mg/
kg and 4 mg/kg) TIW by i.p. injection. While the treatment was
well tolerated as proved by no significant weight loss, IPA-3
significantly suppressed tumor growth (Fig. 6A) and resulted in
lower tumor weights (Fig. 6B). In addition, Western blotting
analysis showed that IPA-3 reduced the phosphorylation of PAK1
and its downstream target JNK (Fig. 6C). Taken together, these
results indicated that IPA-3 can suppress tumorigenesis in vivo by
reducing the PAK1 activity.
Discussion
PAK1 is involved in a complex signaling transduction network
which is linked to various cellular processes, including cytoskeleton
modeling, cell motility, survival and proliferation, and cell cycle
progression [5]. Deregulated or hyper-activated PAK1 is com-
monly associated with HCC [19]. Thus, PAK1 has become a
potential therapeutic target in controlling tumorigenesis and
metastasis of HCC [22]. IPA-3 has been identified to be an
allosteric small molecule inhibitor of PAK1 [8]. With little or less
reports of IPA-3 in the treatment of human HCC, we employed
various in vitro and in vivo experiments to investigate the anti-
tumorigenic ability of IPA-3 treatment on human HCC cell lines.
In this study, we demonstrated that IPA-3 could inhibit the
proliferation rate of HepG2, H2P, H2M, and MHCC97L cells in
dose- and time-dependent manners. Moreover, IPA-3 significantly
inhibited the colony-formation ability of both H2M and HepG2
cells, indicating its suppressive effect on HCC cell proliferation.
Also, the results from the BrdU labeling assay indicated that IPA-3
significantly inhibited the H2P, H2M, HepG2 and MHCC97L
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cell growth in dose- and time-dependent manners. Notably, IPA-3
has no effect on the MIHA cells in all the cell proliferation assays,
indicating that non-transformed hepatocytes or cells with a low
endogenous PAK1 level are not sensitive to IPA-3. Furthermore,
the nude mice xenograft assay demonstrated that IPA-3 can
significantly suppress the HCC tumor growth in vivo.
Given that PAK1 has a pivotal role in controlling cell
proliferation, the suppression on cell proliferation by IPA-3 could
be a result of apoptosis induction. We demonstrated that
administration of IPA-3 exhibited a pro-apoptotic activity of
H2M cells by using annexin V-7ADD staining assay followed by
flow cytometry analysis. This result showed that IPA-3 could
significantly induce the apoptosis of H2M cells. Moreover, IPA-3
treatment of H2M cells could lead to an up-regulation of cleaved
caspase 3 and down-regulation of cleaved PARP1, which is an
apoptotic marker, as well as phosphorylated PAK1. Although the
mechanism by which IPA-3 induces the apoptosis of HCC cells is
not completely known, PAK1 has been shown to phosphorylate
the anti-apoptotic protein, BAD, to suppress the apoptosis of
cancer cells [23]. Taken together, these results suggested that the
inhibitory effect of IPA-3 on HCC cells may be attributed to the
suppression of PAK1-mediated inhibition of apoptosis.
Previous studies reported that PAK1 enhance HCC cell
migration by downregulating the formation of stress fiber and
focal adhesion complex [4]. In the present study, firstly, we
demonstrated the inhibitory effect of IPA-3 on FBS- and TNF-a-
induced phosphorylation of PAK1 in HCC cell lines, which was
consistent with the earlier findings that IPA-3 impeded both basal
and PDGF-stimulated PAK1 activation in fibroblasts [8].
Secondly, we showed that IPA-3 was capable to stabilize these
formations, most likely through the inhibition of PAK1 activity by
using immunofluorescence staining. Lastly, we further confirmed
that IPA-3 treatment significantly suppressed the motility of H2M
cells with a high endogenous level of PAK1 using the Transwell
migration assay. Taken together, these results provided the first
evidence that IPA-3 can inhibit HCC cell migration through the
inactivation of PAK1.
To elucidate the molecular mechanism by which IPA-3
inhibited the HCC cell survival, we examined the effect of IPA-
3 in the regulation of NF-kB activity. Constitutive activation of
NF-kB transcription factors is suggested to be associated with
cancer malignancy by conferring an anti-apoptotic effect to cells
[24]. Hence, the inhibitory effect on TNF-a-induced NF-kB
activity by IPA-3 might suggest a potential use for controlling
HCC tumorigenesis. Our data demonstrated that treatment of
IPA-3 not only abolished the nuclear translocation of NF-kB, but
also remarkably inhibited the activity of the NF-kB transcriptional
targets, MMP-9 and COX-2, which were also induced by TNF-a.
This result correlated well with the earlier findings on human
dermal fibroblasts with an overexpression of a dominant inactive
(K299R) mutant of PAK1 that TNF-a-induced expression and
activation of MMP-9 were highly dependent on PAK1 activity
[19]. Moreover, the results of this study showed that NF-kB
activation contributed to TNF-a-induced COX-2 induction in
H2M cells and IPA-3 inhibited TNF-a-induced COX-2 gene
expression. This result is consistent with the previous findings that
the reduction in PAK1 with siRNA decreased COX-2 expression
in papilloma cells and reduced nuclear localization of NF-kB [25].
In addition, we assessed the anti-tumorigenic ability of IPA-3 by a
nude mouse xenograft assay. IPA-3 showed a significantly
reduction in tumor growth from the MHCC97L cells and the
effect of IPA-3 on PAK1 activity was demonstrated by the
reduction of the phosphorylation levels of PAK1 and JNK. These
data further support the reduction of in vitro PAK1 kinase activity,
suggesting that IPA-3 regulates HCC tumorigenesis by inhibiting
the PAK1/JNK axis.
Apart from IPA-3, many inhibitors have been shown to suppress
PAK1 activity. However, those targeting the evolutionary
conserved ATP-binding pocket of kinases may not be specific
and cause drug toxicity [26,27]. By allosteric inhibition, the non-
ATP competitive inhibitor, IPA-3, achieves a remarkably high
selectivity that only exhibited off-target effects (.50% inhibition)
on 9 out of 214 kinases tested [8]. In our study, IPA-3 treatment
suppresses both in vitro and in vivo HCC cell growth, at least in
part, via the inhibition of PAK1. These results clearly explain that
IPA-3 is able to inhibit PAK1 activity not only prior to
autophosphorylation. Furthermore, PAK1 is rapidly cycling
between the active and inactive states [28] and this increases the
opportunity for IPA-3 to interact with the inactivated PAK1 in
living cells. Upon binding of IPA-3 to its regulatory domain, PAK1
is believed to undergo a conformational change where T423 is
exposed [8,9]. Moreover, the catalytically inactive PAK1 cannot
be reactivated via phosphorylation by exogenous kinases [8].
In summary, our data demonstrated that IPA-3 can suppress
HCC cell proliferation and motility, enhance cell death as well as
restrain liver tumor development, progression and tumorigenicity
by modulating the regulators involved in proliferation, migration
and apoptosis. The current study provides supportive evidences for
the potential application of IPA-3 in HCC treatment and the
specificity of IPA-3 in targeting PAK1, suggesting that IPA-3 is a
potential therapeutic target for the treatment of HCC and may be
more effective on the advanced cancers. One of the possible
explanations for that is the high endogenous PAK1 activity in the
metastatic HCC cells.
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Figure S1 The effect of IPA-3 on PAK1. Western blotting
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treatment.
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